Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



MS Patients Are Adequately, But Not Optimally, Treated for Depression

Canadian study finds that access to antidepressant drugs is not alleviating depressive symptoms in many patients

A new Canadian study, published in the International Journal of MS Care, has concluded that the majority of patients with concurrent multiple sclerosis (MS) and depression are receiving antidepressant treatment. Despite this, however, many of these patients continue to report depressive symptoms.

MS and depression co-occurrence is a big concern, and some reports estimate that up to 50% of MS patients suffer from depression at some time point in their life. Earlier studies have also shown that a large proportion of MS patients — up to 65% — do not receive adequate treatment for their depressive symptoms.

The new study by Aida Raissi and colleagues at Hotchkiss Brain Institute set out to investigate how many MS patients received drug treatment for depression. The study, titled “Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis,“ also aimed to determine which types of treatment were used and to identify characteristics of patients receiving antidepressant drugs.

Using a large number of questionnaires and assessment tools for depression, antidepressant treatment, and MS — as well as measurements for investigating neurological impairment and quality of life — researchers screened 152 people at an outpatient MS clinic in Calgary, Canada.

The study found that 13% of the participants were currently depressed, and 39% reported being depressed at some point in their lives. Of those currently depressed, 65% were taking antidepressant agents. No specific characteristics were associated with antidepressant use, but the team observed that women and older individuals were slightly overrepresented, a trend that might mirror antidepressant demographics in the general population.

Antidepressant drugs were not the sole treatment employed in this group of patients; 19% received only non-drug treatment (psychotherapy), and a further 44% combined drug use and psychotherapy.

The team then adjusted the analysis by taking into consideration patients using antidepressants without having depressive symptoms, and found that 86% of the depressed MS patients received treatment for their depression — a significant improvement from previous reports.

While the authors note a significant improvement in antidepressant treatment coverage in this MS cohort compared to previous reports, they raise some concerns regarding the generalization of their results. Canada is the world’s third leading consumer of antidepressant drugs, behind Iceland and Australia. Considering the study’s small size (152 patients), the findings might not be relevant in other countries.

The team also found that a relatively large proportion of patients were having depressive symptoms in spite of their treatment. The study, however, did not report treatment dose or duration, and the authors argue that further research is needed to explore the reasons for a lack of treatment response.

Previously developed guidelines for the treatment of depression in MS by the Canadian Network for Mood and Anxiety Treatments recommends using antidepressant drugs in combination with psychotherapy focusing on coping strategies. The authors, therefore, noted that the lack of treatment response might mirror the high proportion of patients (38%) receiving only drug therapy.

The study concludes that, since treatment seems to be reaching most depressed patients, optimization of treatment strategies should be a priority for physicians treating MS patients with concurrent depression.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News